TY - JOUR
T1 - An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D 2 and D 3 receptors
AU - Lan, Hongxiang
AU - Teeter, Martha M.
AU - Gurevich, Vsevolod V.
AU - Neve, Kim A.
PY - 2009/1
Y1 - 2009/1
N2 - Dopamine D 2 and D 3 receptors are similar subtypes with distinct interactions with arrestins; the D 3 receptor mediates less agonist-induced translocation of arrestins than the D 2 receptor. The goals of this study were to compare nonphosphorylated arrestin-binding determinants in the second intracellular domain (IC2) of the D 2 and D 3 receptors to identify residues that contribute to the differential binding of arrestin to the subtypes. Arrestin3 bound to glutathione transferase (GST) fusion proteins of the D 2 receptor IC2 more avidly than to the D 3 receptor IC2. Mutagenesis of the fusion proteins identified a residue at the C terminus of IC2, Lys149, that was important for the preferential binding of arrestin3 to D 2-IC2; arrestin binding to D 2-IC2-K149C was greatly decreased compared with wild-type D 2-IC2, whereas binding to the reciprocal mutant D 3-IC2- C147K was enhanced compared with wild-type D 3-IC2. Mutating this lysine in the full-length D 2 receptor to cysteine decreased the ability of the D 2 receptor to mediate agonist- induced arrestin3 translocation to the membrane and decreased agonist-induced receptor internalization in human embryonic kidney 293 cells. The reciprocal mutation in the D 3 receptor increased receptor-mediated translocation of arrestin3 without affecting agonist-induced receptor internalization. G protein-coupled receptor crystal structures suggest that Lys149, at the junction of IC2 and the fourth membrane- spanning helix, has intramolecular interactions that contribute to maintaining an inactive receptor state. It is suggested that the preferential agonist-induced binding of arrestin3 to the D 2 receptor over the D 3 receptor is due in part to Lys149, which could be exposed as a result of receptor activation.
AB - Dopamine D 2 and D 3 receptors are similar subtypes with distinct interactions with arrestins; the D 3 receptor mediates less agonist-induced translocation of arrestins than the D 2 receptor. The goals of this study were to compare nonphosphorylated arrestin-binding determinants in the second intracellular domain (IC2) of the D 2 and D 3 receptors to identify residues that contribute to the differential binding of arrestin to the subtypes. Arrestin3 bound to glutathione transferase (GST) fusion proteins of the D 2 receptor IC2 more avidly than to the D 3 receptor IC2. Mutagenesis of the fusion proteins identified a residue at the C terminus of IC2, Lys149, that was important for the preferential binding of arrestin3 to D 2-IC2; arrestin binding to D 2-IC2-K149C was greatly decreased compared with wild-type D 2-IC2, whereas binding to the reciprocal mutant D 3-IC2- C147K was enhanced compared with wild-type D 3-IC2. Mutating this lysine in the full-length D 2 receptor to cysteine decreased the ability of the D 2 receptor to mediate agonist- induced arrestin3 translocation to the membrane and decreased agonist-induced receptor internalization in human embryonic kidney 293 cells. The reciprocal mutation in the D 3 receptor increased receptor-mediated translocation of arrestin3 without affecting agonist-induced receptor internalization. G protein-coupled receptor crystal structures suggest that Lys149, at the junction of IC2 and the fourth membrane- spanning helix, has intramolecular interactions that contribute to maintaining an inactive receptor state. It is suggested that the preferential agonist-induced binding of arrestin3 to the D 2 receptor over the D 3 receptor is due in part to Lys149, which could be exposed as a result of receptor activation.
UR - http://www.scopus.com/inward/record.url?scp=58849087235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58849087235&partnerID=8YFLogxK
U2 - 10.1124/mol.108.050542
DO - 10.1124/mol.108.050542
M3 - Article
C2 - 18820126
AN - SCOPUS:58849087235
SN - 0026-895X
VL - 75
SP - 19
EP - 26
JO - Molecular pharmacology
JF - Molecular pharmacology
IS - 1
ER -